Sei Investments Co. Acquires 44,474 Shares of Enovis Corporation $ENOV

Sei Investments Co. raised its holdings in Enovis Corporation (NYSE:ENOV) by 37.1% during the 1st quarter, HoldingsChannel.com reports. The fund owned 164,253 shares of the company’s stock after acquiring an additional 44,474 shares during the quarter. Sei Investments Co.’s holdings in Enovis were worth $3,737,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of ENOV. Arax Advisory Partners purchased a new position in shares of Enovis during the fourth quarter worth about $29,000. EverSource Wealth Advisors LLC increased its position in shares of Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the last quarter. Danske Bank A S purchased a new stake in Enovis in the third quarter valued at approximately $64,000. iSAM Funds UK Ltd purchased a new stake in Enovis in the third quarter valued at approximately $80,000. Finally, Brown Brothers Harriman & Co. bought a new stake in Enovis during the third quarter valued at approximately $90,000. Institutional investors own 98.45% of the company’s stock.

Insider Buying and Selling

In other Enovis news, insider Oliver Engert bought 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the transaction, the insider directly owned 51,840 shares in the company, valued at $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have acquired 4,200 shares of company stock valued at $92,084. 2.90% of the stock is owned by company insiders.

Enovis Stock Down 12.2%

Shares of ENOV opened at $26.50 on Friday. Enovis Corporation has a 1 year low of $19.14 and a 1 year high of $34.28. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05. The stock has a 50 day simple moving average of $24.54 and a two-hundred day simple moving average of $23.95. The firm has a market cap of $1.53 billion, a P/E ratio of -1.33 and a beta of 1.34.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The firm had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. During the same period in the previous year, the business posted $0.79 EPS. The business’s quarterly revenue was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts forecast that Enovis Corporation will post 3.12 earnings per share for the current fiscal year.

Enovis News Summary

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q2 earnings exceeded expectations: Enovis reported adjusted EPS of $0.90, above the $0.83–$0.85 analyst estimates and up from $0.79 a year earlier. Revenue increased 3.2% year over year to $582.8 million, narrowly beating the $581.8 million consensus. Enovis Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Reconstructive business remained strong: Reconstructive sales grew 8% on a reported basis and 6% organically, helping drive total second-quarter sales growth of 3% reported and 5% organically. Management reaffirmed its full-year 2026 revenue, adjusted EBITDA, adjusted EPS and free-cash-flow-conversion targets. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: Analyst support increased: BTIG Research raised its Enovis price target to $40 from $39 and assigned a Buy rating, indicating substantial potential upside from recent trading levels. BTIG Raises Enovis Price Target
• Neutral Sentiment: 2026 guidance was reaffirmed: Enovis forecast revenue of approximately $2.3 billion to $2.4 billion and EPS of $3.52 to $3.73. The EPS range broadly brackets the $3.54 consensus estimate, offering limited evidence of a meaningful outlook increase.
• Negative Sentiment: Investors may have wanted stronger growth or guidance: Although profitability beat estimates, reported sales growth remained modest, and the company continues to report a negative net margin. Those factors may be overshadowing the quarterly beat and positive analyst action.

Wall Street Analysts Forecast Growth

ENOV has been the subject of a number of research reports. William Blair initiated coverage on shares of Enovis in a research note on Friday, April 17th. They issued an “outperform” rating for the company. Wells Fargo & Company lowered their price objective on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. BMO Capital Markets assumed coverage on shares of Enovis in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $29.00 target price for the company. Evercore set a $32.00 target price on Enovis in a research note on Monday, July 6th. Finally, BTIG Research raised their price target on Enovis from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.